AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
zavegepant 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| calcitonin gene-related peptide receptor antagonists | 5713 | 1337918-83-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP3K21,MAPK10,MAPK7,MET,NTRK2,PDK1,PDK2,PDK4,PRKDC,SIK2,SIK3,TEK | 26 | |||
| kinase-selectivity-class | AXL,CAMK2D,SIK2 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 9, 2023 | FDA | PFIZER INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dysgeusia | 445.23 | 73.09 | 97 | 579 | 52463 | 90575308 |
| Nasal discomfort | 229.28 | 73.09 | 39 | 637 | 5509 | 90622262 |
| Throat irritation | 107.92 | 73.09 | 31 | 645 | 48664 | 90579107 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dysgeusia | 72.69 | 57.72 | 14 | 29 | 34175 | 42587117 |
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N02CD08 | NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Calcitonin gene-related peptide (CGRP) antagonists |
| MeSH PA | D000077221 | Calcitonin Gene-Related Peptide Receptor Antagonists |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
| FDA EPC | N0000193917 | Calcitonin Gene-related Peptide Receptor Antagonist |
| FDA MoA | N0000193918 | Calcitonin Gene-related Peptide Receptor Antagonists |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:65023 | anti-asthmatic agent |
| CHEBI has role | CHEBI:196956 | calcitonin gene-related peptide receptor antagonist |
Related Drugs by ATC class:
N02CD Calcitonin gene-related peptide (CGRP) antagonists 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Migraine with aura | indication | 4473006 | DOID:10024 |
| Migraine without aura | indication | 56097005 | DOID:12783 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 10MG BASE/SPRAY | ZAVZPRET | PFIZER | N216386 | March 9, 2023 | RX | SPRAY, METERED | NASAL | 8481546 | June 26, 2034 | ADMINISTRATION OF ZAVEGEPANT FOR ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 10MG BASE/SPRAY | ZAVZPRET | PFIZER | N216386 | March 9, 2023 | RX | SPRAY, METERED | NASAL | March 9, 2028 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Calcitonin gene-related peptide type 1 receptor | GPCR | ANTAGONIST | Ki | 10.64 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| CHEBI:229643 | CHEBI |
| CHEMBL2397415 | ChEMBL_ID |
| C584752 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11513 | IUPHAR_LIGAND_ID |
| DB15688 | DRUGBANK_ID |
| 4042290 | VANDF |
| C5383284 | UMLSCUI |
| CHEMBL4650220 | ChEMBL_ID |
| 11512 | INN_ID |
| 1414976-20-7 | SECONDARY_CAS_RN |
| 53472683 | PUBCHEM_CID |
| 365618 | MMSL |
| 41302 | MMSL |
| d10020 | MMSL |
| 019338 | NDDF |
| 019339 | NDDF |
| D11898 | KEGG_DRUG |
| ODU3ZAZ94J | UNII |
| 2637955 | RXNORM |
| ODU3ZAZ94J | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ZAVZPRET | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-3500 | SPRAY | 10 mg | NASAL | NDA | 30 sections |
| ZAVZPRET | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63539-135 | SPRAY | 10 mg | NASAL | NDA | 30 sections |